Quantcast

GateWay Community College CEI Company VisionGate Attacks the World’s Number One Cancer Killer: Lung Cancer

September 28, 2013

VisionGate, a pioneering biotechnology company recently accepted into the Center for Entrepreneurial Innovation (CEI) at GateWay Community College, is developing revolutionary non-invasive diagnostic technology that can enable early-cancer detection that could save thousands of lives.

Phoenix, AZ (PRWEB) September 28, 2013

Nearly 160,000 Americans are expected to lose their lives to lung cancer this year alone, according to the American Cancer Society, making it the world’s number one cancer-related killer.

VisionGate, a pioneering biotechnology company recently accepted into the Center for Entrepreneurial Innovation (CEI), is developing revolutionary non-invasive diagnostic technology that can enable early-cancer detection that could save thousands of lives.

“This is a company that could literally change the way the medical world views lung cancer and could ultimately impact the millions of people worldwide who are affected by this terrible disease,” said Jeff Saville, CEI Executive Director.

VisionGate was one of several biotechnology companies accepted in June as a residential client into the Phoenix business incubator.

The company looks to take advantage of the center’s wet lab, light manufacturing space and business services in order to complete development and prepare for commercialization of its patented Cell-CT™ platform for the automated analysis of high-resolution 3D images of human cells. This is the technology that is enabling VisionGate to develop an accurate and cost-effective sputum-based diagnostic test for lung cancer.

“During my pharmaceutical career I worked in the oncology division, which led me to want to make a difference and save lives,” said VisionGate President Scarlett Spring. “VisionGate’s technology has the potential to enable the early detection of lung cancer in high risk individuals, thereby allowing treatment to begin early in the disease process, when cures are still feasible. VisionGate is committed to achieving business success by applying its technology to make a real difference in the diagnosis and treatment of lung cancer and other deadly diseases.”

Dr. Alan Nelson, the company’s founder and CEO states that, “I have devoted my professional life to the eradication of cancer through early detection, beginning with breast cancer, then cervical cancer, and now lung cancer. The future for additional cancer detection using VisionGate’s Cell-CT platform no doubt will impact other cancers such as bladder cancer, oral cancer, pancreatic cancer and prostate cancer—all within our sights.”

Other biotech-related companies that joined CEI’s incubation program in June include OneClickMed, which connects the biomedical and healthcare industries into one Global Medical Community and Portal, as well as Marsh Designs, which creates safe and flexible laboratory support equipment for neuroscientists.

“CEI was funded with the express purpose of creating jobs for the city of Phoenix, particularly through the bioscience startups that we are equipped to support,” said Saville. “And these brilliant entrepreneurs we have recruited have a great opportunity to leave their mark on the biotech industry in Arizona and the world.”

###

About CEI

An initiative of the Maricopa Corporate College, the Center for Entrepreneurial Innovation is a community-based business incubator located on the campus of GateWay Community College in the heart of Discovery Triangle. With funding from the US Economic Development Administration, City of Phoenix and Maricopa Community Colleges, CEI provides targeted business services and proactive business support to create a systematic link between technology development, compelling markets and opportunities; entrepreneurial and managerial talent development; early stage capital sourcing; and education and training, interns, coaching and business counseling.

For the original version on PRWeb visit: http://www.prweb.com/releases/cei/visiongate/prweb11169540.htm


Source: prweb



comments powered by Disqus